88 completed, 4 withdrawn, 2 recruiting, 2 unknown. 43 Phase 3, 24 Phase 4, 21 Phase 2, 7 Phase 1, 3 Not applicable.
Follow indacaterol: new trials by email Literature Review of indacaterol trials Research Report on indacaterol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparative Efficacy of Once-daily LAMA/LABA Combinations Versus Tiotropium on Constant-work-rate Cycle Endurance in COPD Tiotropium, Olodaterol, Umeclidinium - COPD (Chronic Obstructive Pulmonary Disease) | Not applicable | Suspended | Medical University of Bialystok | 100 | 2024-03-11 | 2026-10-02 |
| ANTES B+ Clinical Trial Trelegy Ellipta 100/62.5/25Mcg Inh 30D, Brimica, Duaklir - Chronic Obstructive Pulmonary Disease | Phase 4 | Terminated | Fundacio Privada Mon Clinic Barcelona | 48 | 2024-02-29 | 2025-08-14 |
| U-LABA/ICS Effects on Exercise Performance, Indacaterol Indacaterol and Mometasonefluroate (low dose), Placebo, Indacaterol and Mometasonefluroate (high dose) - Exercise Performance | Not applicable | Recruiting | Morten Hostrup, PhD | 30 | 2024-01-15 | 2025-04-09 |
| Role of Lung Function for Exercise Capacity in Well-trained Individuals Vilanterol and Fluticasone Furoate, Indacaterol and Mometasone Furoate, Placebo - Exercise Performance | Not applicable | Recruiting | Morten Hostrup, PhD | 60 | 2023-10-03 | 2025-04-09 |
| Study to Compare Relative Bioavailability of 3 Indacaterol/Glycopyrronium Test Products and Reference Product Indacaterol/glycopyrronium - Healthy Volunteers | Phase 1 | Completed | Orion Corporation, Orion Pharma | 24 | 2022-02-28 | 2022-07-13 |
| Investigating the Effects of QVM149 on MRI Ventilation Defects QVM149, High Dose Dual Therapy (ICS/LABA) - Asthma | Phase 3 | Withdrawn | Dr. Grace Parraga | 2021-12-01 | 2021-12-14 | |
| Anti-inflammatory Effects Glycopyrronium QVM149, QMF149 - Asthma, Allergic Asthma | Phase 3 | Completed | University Medical Center Groningen | 28 | 2020-09-10 | 2023-01-12 |
| Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Indacaterol maleate, Indacaterol acetate, Placebo - Asthma | Phase 2 | Completed | Novartis Pharmaceuticals | 54 | 2017-09-05 | 2021-01-05 |
| RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative Indacaterol/Glycopyrrolate, Placebo - COPD (Chronic Obstructive Pulmonary Disease) | Phase 3 | Completed | University of Michigan | 780 | 2017-08-29 | 2023-04-13 |
| Efficacy and Safety of Indacaterol Acetate Delivered Via the Concept1 Inhalation Device in Children Greater or Equal to 6 and Less Than 12 Years of Age With Asthma Indacaterol acetate 75 μg, Indacaterol acetate 150 μg - Asthma | Phase 2 | Completed | Novartis Pharmaceuticals | 79 | 2017-04-18 | 2020-01-27 |
| Drug Utilization Study for Olodaterol Olodaterol, Indacaterol - Pulmonary Disease, Chronic Obstructive | Completed | Boehringer Ingelheim | 27606 | 2017-02-08 | 2019-06-27 | |
| Study of QMF149 (150/80 µg) Compared With MF Twisthaler® (200 µg) in Patients With Asthma QMF149 150/80 μg, MF 200 μg - Mild Asthma | Phase 3 | Completed | Novartis Pharmaceuticals | 802 | 2017-01-16 | 2026-01-13 |
| Effect of a LAMA and a uLABA on the Methacholine Dose-response Curve Glycopyrronium, Indacaterol - Asthma | Phase 4 | Completed | University of Saskatchewan | 31 | 2016-10-01 | 2017-06-14 |
| Ultibro® Versus Spiriva® Alone to Reduce Exertional Dyspnea in Patients With Moderate to Severe COPD Ultibro®, Spiriva® - COPD | Phase 4 | Completed | Laval University | 50 | 2016-06-01 | 2019-06-07 |
| Effects of Long Acting Bronchodilators on CARDiac Autonomic Control in Chronic Obstructive Pulmonary Disease (COPD) Indacaterol, Glycopyrronium, Tiotropium - Chronic Obstructive Pulmonary Disease | Phase 4 | Completed | Centre Hospitalier Universitaire de Besancon | 42 | 2016-03-01 | 2021-08-03 |
| Utilizing Wearable Device to Observe the Clinical Response of COPD Patients Treated With Combined Bronchodilator and Home-based Pulmonary Rehabilitation Program Indacaterol/Glycopyrronium - Chronic Obstructive Pulmonary Disease | Phase 4 | Unknown | Taipei Medical University Shuang Ho Hospital | 50 | 2016-01-01 | 2018-04-30 |
| A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma Indacaterol acetate/Mometasone furoate, Mometasone furoate, Salmeterol xinafoate/fluticasone propionate - Asthma | Phase 3 | Completed | Novartis Pharmaceuticals | 2216 | 2015-12-29 | 2020-03-05 |
| Single Dose Ultibro Breezhaler by Sd-DPI Versus Ipratropium/Salbutamol by Nebulizer in COPD indacaterol/glycopyrronium 110/50 Breezhaler®, Placebo by Breezhaler®, ipratropium/salbutamol 0,5 mg, 2,5 mg by nebulisation - COPD | Phase 4 | Completed | Wouter H. van Geffen | 40 | 2015-12-01 | 2017-10-11 |
| Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects Dose 1, AZD8871 50 μg (Part 1), Dose 2, AZD8871 100 μg (Part 1), Dose 3, AZD8871 300 μg (Part 1) - Asthma (Part 1), COPD (Part 2) | Phase 1 | Completed | AstraZeneca | 134 | 2015-10-01 | 2018-11-08 |
| Pulmonary Gas Exchange Response to Indacaterol in COPD Arterial blood gases, Cardiac Output, Vital signs - Chronic Obstructive Pulmonary Disease | Phase 4 | Unknown | Hospital Clinic of Barcelona | 20 | 2015-10-01 | 2015-09-11 |
Showing 20 of 98. Sign in to see all of them.
Pulmonary Disease, Chronic Obstructive (73) · Asthma (19) · Dyspnea (6) · Lung Diseases (3) · Motor Activity (2) · Bronchial Diseases (1) · Heart Failure (1) · Hepatic Insufficiency (1) · Hypoxia (1) · Lung Diseases, Obstructive (1) · Respiratory Sounds (1) · Signs and Symptoms, Respiratory (1) · Smoking Cessation (1) · Tachycardia (1)
Novartis Pharmaceuticals (51) · Novartis (20) · AstraZeneca (3) · Morten Hostrup, PhD (2) · National Institute of Respiratory Diseases, Mexico (2) · University of Milan (2) · Boehringer Ingelheim (1) · Centre Hospitalier Universitaire de Besancon (1) · Centro Cardiologico Monzino (1) · Dr. Grace Parraga (1) · Fundacio Privada Mon Clinic Barcelona (1) · GlaxoSmithKline (1) · Hospital Clinic of Barcelona (1) · Irmandade Santa Casa de Misericórdia de Porto Alegre (1) · Laval University (1)
United States (30) · Germany (29) · Spain (24) · Hungary (19) · Italy (18) · Canada (16) · France (16) · United Kingdom (16) · Slovakia (15) · Belgium (14) · Netherlands (13) · Poland (13) · Turkey (Türkiye) (13) · Denmark (11) · India (11)
Morten Hostrup, PhD (2) · Pierachille Santus, MD, PhD (2) · Arvind Deva Manoharan, MBChB (1) · Brian Lipworth, MD (1) · Carin Jorup, MD (1) · Chul-Gyu Yoo, MD PhD (1)
PMID 21227674, PMID 21397482, PMID 22206353, PMID 11019457, PMID 16322646, PMID 16799080, PMID 17310045, PMID 17951621, PMID 18625750, PMID 20920365, PMID 22003288, PMID 22158330, PMID 22177371, PMID 22544891, PMID 23020650, PMID 31539467, PMID 36472162, PMID 8810608, PMID 12114338, PMID 16055868, PMID 16144890, PMID 16310554, PMID 16396956, PMID 16844726, PMID 16914336, PMID 17088091, PMID 17532532, PMID 17678942, PMID 17765528, PMID 18479895, PMID 18804362, PMID 18836213, PMID 19556519, PMID 20211002, PMID 20463178, PMID 20522841, PMID 20850959, PMID 20956145, PMID 20978028, PMID 21184620, PMID 21349928, PMID 21367594, PMID 21428765, PMID 21498063, PMID 21615886, PMID 21622587, PMID 22035851, PMID 22714646, PMID 23040786, PMID 23155808
2009 (4), 2008 (3), 2015 (2), 2016 (2), 2023 (1), U01HL128952 (1)